臨床的にASCVDを発症した患者または初回ASCVD発症リスクのある患者におけるAZD0780のLDL-Cに対する効果を評価する第III相試験

基本情報

NCT ID

NCT07000123

ステータス

実施中（募集終了）

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

3,046

治験依頼者名

AstraZeneca

概要

This is a study to evaluate the efficacy and safety of AZD0780 in adults with clinical ASCVD or who are at risk for a first ASCVD event and who have elevated LDL-C. AZD0780 is a small molecule that reduces the amount of LDL-C in the blood. Placebo will be used for comparison, and neither the participants nor the Investigators will know who is receiving the AZD0780 medication and who is receiving the placebo until the end of study. The total length of the study for an individual participant will be up to approximately 56 weeks, including a screening period of up to 14 days, treatment with AZD0780 or placebo for 52 weeks, and a safety follow-up period of 10 days.

対象疾患

介入

依頼者（Sponsor）